1. Home
  2. JBLU vs SRPT Comparison

JBLU vs SRPT Comparison

Compare JBLU & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$4.56

Market Cap

2.1B

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$20.10

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBLU
SRPT
Founded
1998
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2002
2000

Fundamental Metrics

Financial Performance
Metric
JBLU
SRPT
Price
$4.56
$20.10
Analyst Decision
Sell
Hold
Analyst Count
13
29
Target Price
$4.91
$25.85
AVG Volume (30 Days)
17.9M
2.9M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
N/A
EPS
N/A
2.99
Revenue
$9,062,000,000.00
$2,198,237,000.00
Revenue This Year
$12.11
N/A
Revenue Next Year
$6.75
N/A
P/E Ratio
N/A
$6.69
Revenue Growth
N/A
15.58
52 Week Low
$3.87
$14.68
52 Week High
$6.62
$25.32

Technical Indicators

Market Signals
Indicator
JBLU
SRPT
Relative Strength Index (RSI) 43.50 50.21
Support Level $3.87 $19.53
Resistance Level $5.12 $20.54
Average True Range (ATR) 0.16 1.32
MACD 0.03 -0.30
Stochastic Oscillator 66.35 14.60

Price Performance

Historical Comparison
JBLU
SRPT

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: